ReviewMolecular cell2015
Choosing the Right Tool for the Job: RNAi, TALEN, or CRISPR.
Review in Molecular cell, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 230 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
230 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Pooled it
- Ethical and legal implications of gene editing in plant breeding: a systematic literature review.Journal of Zhejiang University. Science. B · 2023Pooled it
- Pooled it
- Pooled it
- Selective and Potent First-in-Class CRBN-Dependent Molecular Glue Degraders of WW Domain-Binding Protein 4.Angewandte Chemie (International ed. in English) · 2026Article
- Artificial Intelligence in genomics: a comprehensive survey of methods, resources, challenges, and prospects.Briefings in bioinformatics · 2026Review
- Precision editing to improve fruit traits: CRISPR/Cas into the picture.Protoplasma · 2026Review
- A Modified Methyl Transferase Cofactor to Selectively Silence Gene Expression in Escherichia coli.Chembiochem : a European journal of chemical biology · 2026Article
- Insights from pooled CRISPRi single-cell screens in K562 cells reveal gene functions, regulatory networks, and highlight opportunities and limitations.BMC genomics · 2026Article
- Targeted Gene Expression Modulation Using CRISPR/dCas9 to Investigate Pathogenic Outcomes in Tomato.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Advances in plant metabolic engineering through synthetic biology.Frontiers in plant science · 2026Review
- New Insights into the Mechanism of Insulin-like Peptide 3 (International journal of molecular sciences · 2025Article
- An unbiased whole-genome open reading frame overexpression screen identifies B3GALT2, a novel inducer of cellular ASO activity.Molecular therapy. Nucleic acids · 2025Article
- Multiplexed inhibition of immunosuppressive genes with Cas13d for combinatorial cancer immunotherapy.Nature biotechnology · 2025Article
- Innovative gene engineering and drug delivery systems for dendritic cells in cancer immunotherapy.Journal of biomedical science · 2025Review
- Gold-siRNA supraclusters enhance the anti-tumor immune response of stereotactic ablative radiotherapy at primary and metastatic tumors.Nature biotechnology · 2025Article
- CRISPR-Cas9-driven antigen conversion of clinically relevant blood group systems.Human molecular genetics · 2025Article
- Review
- Global stabilization of Boolean networks with applications to biomolecular network control.Scientific reports · 2025Article
- Genes Affecting Cotton Fiber Length: A Systematic Review and Meta-Analysis.Plants (Basel, Switzerland) · 2025Article
170 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The most widely used approach for defining gene function is to reduce or completely disrupt its normal expression. For over a decade, RNAi has ruled the lab, offering a magic bullet to disrupt gene expression in many organisms. However, new biotechnological tools--specifically CRISPR-based technologies--have become available and are squeezing out RNAi dominance in mammalian cell studies. These seemingly competing technologies leave research investigators with the question: "Which technology should I use in my experiment?" This review offers a practical resource to compare and contrast these technologies, guiding the investigator when and where to use this fantastic array of powerful tools.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.